See more : Simran Farms Limited (SIMRAN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Achieve Life Sciences, Inc. (ACHV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Achieve Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mediaset España Comunicación, S.A. (GETVY) Income Statement Analysis – Financial Results
- Doosan Fuel Cell Co., Ltd. (33626L.KS) Income Statement Analysis – Financial Results
- Drägerwerk AG & Co. KGaA (DRW3.DE) Income Statement Analysis – Financial Results
- Citron, Inc. (CTNI) Income Statement Analysis – Financial Results
- Magmatic Resources Limited (MAG.AX) Income Statement Analysis – Financial Results
Achieve Life Sciences, Inc. (ACHV)
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 8.75M | 408.41K | 12.10M | 5.10M | 18.90M | 16.60M | 4.50M | 1.10M |
| Cost of Revenue | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.22M | 3.69M | -600.00K | -800.00K | -600.00K | -500.00K | -300.00K | 5.50M |
| Gross Profit | -228.00K | -236.00K | -250.00K | -255.00K | -254.00K | -282.00K | -282.00K | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 3.53M | -3.28M | 12.70M | 5.90M | 19.50M | 17.10M | 4.80M | -4.40M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.33% | -803.51% | 104.96% | 115.69% | 103.17% | 103.01% | 106.67% | -400.00% |
| Research & Development | 15.81M | 30.08M | 23.97M | 6.88M | 9.67M | 5.87M | 3.10M | 14.79M | 25.11M | 46.22M | 55.32M | 39.95M | 21.55M | 18.48M | 24.16M | 7.82M | 27.15M | 41.10M | 24.49M | 10.71M | 7.65M | 8.96M | 5.22M | 3.26M | 5.60M | 10.50M | 11.60M | 11.20M | 7.20M | 0.00 |
| General & Administrative | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 0.00 | 5.84M | 3.96M | 3.29M | 8.22B | 7.58B | 5.57B | 5.87B | 3.01B | 3.24B | 3.31M | 3.95M | 5.78M | 6.55M | 7.20M | 3.81M | 2.20M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.21B | -7.57B | -5.56B | -5.86B | -3.01B | -3.24B | 888.00 | 432.52K | 720.00K | -50.00K | 0.00 | -10.00K | 0.00 | 0.00 |
| SG&A | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 6.23M | 5.84M | 3.96M | 3.29M | 8.22M | 7.58M | 5.57M | 5.87M | 3.01M | 3.24M | 3.31M | 4.38M | 6.50M | 6.50M | 7.20M | 3.80M | 2.20M | 3.50M |
| Other Expenses | 0.00 | -1.55M | -58.00K | -49.00K | 133.00K | 126.00K | 165.00K | 1.06M | 1.95M | 3.23M | 120.00K | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| Operating Expenses | 27.02M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.70M | 17.80M | 19.40M | 15.50M | 9.80M | 3.80M |
| Cost & Expenses | 27.25M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.10M | 17.00M | 18.80M | 15.00M | 9.50M | 9.30M |
| Interest Income | 825.00K | 199.00K | 17.00K | 69.00K | 170.00K | 171.00K | 21.00K | 203.00K | 119.00K | 35.00K | 150.00K | 292.00K | 220.00K | 86.00K | 47.00K | 210.00K | 2.30M | 2.85M | 714.87K | 289.59K | 213.19K | 468.48K | 539.69K | 692.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.85M | 1.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 531.00K | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 434.00 | 2.98K | 6.82K | 24.63K | 42.14K | 31.67K | 13.86K | 34.06K | 470.00K | 200.00K | 970.00K | 200.00K | 800.00K | 600.00K |
| Depreciation & Amortization | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 188.00K | 244.00K | 223.00K | 227.00K | 100.00K | 75.00K | 52.00K | 50.00K | 89.00K | 655.69K | 609.62K | 586.16K | 515.48K | 380.43K | 580.62K | 258.10K | 357.54K | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| EBITDA | -26.73M | -40.33M | -32.90M | -14.48M | -16.14M | -12.41M | -13.35M | -19.94M | -16.56M | -26.02M | -31.62M | -21.00M | -22.21M | -15.53M | 1.42M | -10.60M | -12.41M | -22.94M | -20.50M | -15.73M | -10.26M | -11.59M | 474.45K | -6.88M | 589.54K | -11.08M | 700.00K | 2.10M | -4.60M | -7.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -318.57% | -103.27% | -110.64% | -128.20% | -167.50% | -538.68% | -41.80% | -10.57% | -55.80% | -71.80% | -114.17% | -257.16% | -6.06% | -41,030.90% | -46,373.91% | 5.42% | -2,724.05% | 12.40% | -237.25% | -2.12% | 7.83% | -108.89% | -727.27% |
| Operating Income | -27.25M | -40.80M | -33.09M | -14.75M | -16.53M | -12.81M | -6.63M | -21.19M | -18.75M | -29.47M | -35.33M | -25.99M | -22.29M | -14.75M | -2.47M | -6.26M | -15.23M | -26.29M | -21.81M | -16.58M | -10.64M | -12.17M | 216.35K | -7.23M | 900.00K | -11.90M | 100.00K | 1.60M | -5.00M | -8.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -418.65% | -103.27% | -108.67% | -118.22% | -129.32% | -405.51% | -108.29% | -9.65% | -31.11% | -75.68% | -117.39% | -264.21% | -6.26% | -42,552.60% | -48,696.39% | 2.47% | -1,770.96% | 7.44% | -233.33% | 0.53% | 9.64% | -111.11% | -745.45% |
| Total Other Income/Expenses | -2.57M | -1.55M | -58.00K | 20.00K | 133.00K | 126.00K | -7.00M | -1.47M | 1.95M | 3.49M | 3.48M | 6.55M | 7.61M | -4.88M | 117.00K | 421.00K | 2.17M | 2.74M | 712.20K | -735.04K | 171.05K | 436.81K | 525.83K | 4.91M | 440.46K | 711.22K | 1.00M | 600.00K | -400.00K | -500.00K |
| Income Before Tax | -29.82M | -42.35M | -33.15M | -14.73M | -16.40M | -12.69M | -13.63M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -15.58M | 2.47M | -10.69M | -15.36M | -26.40M | -21.81M | -16.31M | -10.47M | -11.74M | 742.18K | -2.32M | 430.00K | -11.17M | 1.10M | 2.20M | -5.40M | -8.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -114.45% | 9.65% | -53.11% | -76.30% | -117.90% | -264.16% | -6.16% | -41,868.40% | -46,949.14% | 8.48% | -569.13% | 3.55% | -219.02% | 5.82% | 13.25% | -120.00% | -790.91% |
| Income Tax Expense | 0.00 | -475.00K | -250.00K | -69.00K | -254.00K | -126.00K | -3.05M | -1.06M | -1.95M | -3.49M | -3.48M | -6.55M | -7.61M | -3.00M | -3.01M | -2.06M | -2.17M | -2.74M | -712.20K | -264.96K | -171.05K | -101.48K | 200.00K | -176.94K | 470.00K | -730.00K | 100.00K | 500.00K | 500.00K | 200.00K |
| Net Income | -29.82M | -41.88M | -32.90M | -14.66M | -16.14M | -12.69M | -10.58M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -12.58M | 5.48M | -4.20M | -13.06M | -23.55M | -21.10M | -16.31M | -10.47M | -11.64M | 542.18K | -2.15M | 400.00K | -11.20M | 1.00M | 1.70M | -5.90M | -8.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -92.42% | 21.44% | -20.88% | -64.89% | -105.18% | -255.58% | -6.16% | -41,868.40% | -46,543.20% | 6.20% | -525.81% | 3.31% | -219.61% | 5.29% | 10.24% | -131.11% | -809.09% |
| EPS | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.48K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| EPS Diluted | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.47K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| Weighted Avg Shares Out | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.61K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
| Weighted Avg Shares Out (Dil) | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.65K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
SEATTLE and VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced the Company...
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
SEATTLE and VANCOUVER, British Columbia, May 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced first quarter...
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it...
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs.
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John...
Achieve Life Sciences Announces Refresh to Board of Directors
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes...
Achieve Life Sciences Announces Granting of New Hire Inducement Award
SEATTLE, Wash. and VANCOUVER, British Columbia, March 17, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that...
Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Relations John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan...
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
Company to host conference call March 16, 2023, at 4:30 PM EDT Company to host conference call March 16, 2023, at 4:30 PM EDT
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023 Topline Data Expected in 2Q 2023
Source: https://incomestatements.info
Category: Stock Reports